Breakthru Medicine develops novel therapeutic modalities aimed at treating cancer by targeting hard-to-drug disease mechanisms.
Breakthru Medicine has raised $60.0M in total funding. The most recent round was Series A. The last funding was announced in January 2026.
Breakthru Medicine's investors include Dave Morehead, Fred Eshelman, Mark J. Gergen.
Breakthru Medicine is headquartered in Phoenix, United States.
Breakthru Medicine develops novel therapeutic modalities aimed at treating cancer by targeting hard-to-drug disease mechanisms.
Breakthru Medicine is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Breakthru Medicine — Funding & Investors." VCBacked, January 29, 2026, https://www.vcbacked.co/company/breakthru-medicine. Accessed October 17, 2026.
VCBacked. (2026). Breakthru Medicine — Funding & Investors. Retrieved October 17, 2026, from https://www.vcbacked.co/company/breakthru-medicine
{{cite web |title=Breakthru Medicine — Funding & Investors |url=https://www.vcbacked.co/company/breakthru-medicine |website=VCBacked |access-date=October 17, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated